Scientists from King’s College London have achieved a massive milestone in neurodegenerative medicine by discovering a groundbreaking Alzheimer’s disease drug candidate that actively repairs cellular DNA damage. The experimental molecule, which was originally developed to treat spinal cord injuries, targets the very roots of dementia by successfully reducing severe brain inflammation and restoring critical neural structures. Because the therapy has already cleared initial human safety trials, researchers hope it will provide a significantly faster track toward rolling out next-generation cognitive therapies for aging demographics.
About the Author
